ArticleFrontiers in endocrinology2022

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma.

Wei Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.